A groundbreaking study from Yale reveals the potential of Semaglutide, known by the brand name Wegovy, in significantly reducing heart attack risks and other heart-related issues among obese Americans with cardiovascular disease.
Presented at the American Heart Association Scientific Sessions, this research underscores the drug’s potential beyond diabetes treatment, offering hope to millions.
Semaglutide’s Expanding Horizon
Traditionally known for treating diabetes under the brand Ozempic, Semaglutide has now been shown to benefit individuals without diabetes.
The SELECT trial demonstrated a 20% reduction in major heart events such as heart attacks and strokes in adults over 45 with heart disease and obesity. This finding is crucial, given the increasing prevalence of obesity and related heart conditions.
A Wide-Reaching Impact
The Yale study, published in the journal Obesity, estimates that over 6.6 million Americans fit the criteria to benefit from Semaglutide.
“The potential for population benefit is enormous,” notes Yuan Lu, ScD, the study’s lead author. This comes at a time when the number of people eligible for such treatment has surged by 50% over the past decade.
Addressing Inequities in Health Care Access
The study also sheds light on the disproportionate representation of minoritized and lower socioeconomic groups among those who stand to gain from Semaglutide.
“We need to ensure that everyone who can benefit has access to these medications,” emphasizes Harlan M. Krumholz, MD, SM, highlighting the necessity for equitable health care access.
Conclusion
Semaglutide’s role in heart health management is evolving, offering a beacon of hope for millions grappling with obesity and cardiovascular diseases.
The Yale study not only confirms the drug’s efficacy but also calls for broadening its accessibility across various demographic groups.
As the landscape of heart health treatment evolves, Semaglutide stands out as a key player in combating cardiovascular risks associated with obesity.
The research findings can be found in Obesity.
Copyright © 2023 Knowridge Science Report. All rights reserved.
